DK0495265T3 - Syrelabile koblingsmolekyler - Google Patents

Syrelabile koblingsmolekyler

Info

Publication number
DK0495265T3
DK0495265T3 DK91203439.4T DK91203439T DK0495265T3 DK 0495265 T3 DK0495265 T3 DK 0495265T3 DK 91203439 T DK91203439 T DK 91203439T DK 0495265 T3 DK0495265 T3 DK 0495265T3
Authority
DK
Denmark
Prior art keywords
aralkyl
aryl
lower alkyl
acid
alkylene
Prior art date
Application number
DK91203439.4T
Other languages
Danish (da)
English (en)
Inventor
Petrus Johannes Boon
Ebo Sybren Bos
Franciscus Michael Kaspersen
Original Assignee
Akzo Nobel Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nobel Nv filed Critical Akzo Nobel Nv
Application granted granted Critical
Publication of DK0495265T3 publication Critical patent/DK0495265T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/60—Two oxygen atoms, e.g. succinic anhydride
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/24—Condensed ring systems having three or more rings
    • C07H15/252—Naphthacene radicals, e.g. daunomycins, adriamycins

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Mushroom Cultivation (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
DK91203439.4T 1990-12-31 1991-12-30 Syrelabile koblingsmolekyler DK0495265T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP90203526 1990-12-31

Publications (1)

Publication Number Publication Date
DK0495265T3 true DK0495265T3 (da) 1995-01-02

Family

ID=8205218

Family Applications (1)

Application Number Title Priority Date Filing Date
DK91203439.4T DK0495265T3 (da) 1990-12-31 1991-12-30 Syrelabile koblingsmolekyler

Country Status (17)

Country Link
US (1) US5306809A (de)
EP (1) EP0495265B1 (de)
JP (1) JPH04334377A (de)
KR (1) KR920012063A (de)
AT (1) ATE109476T1 (de)
AU (1) AU646121B2 (de)
CA (1) CA2058595A1 (de)
DE (1) DE69103255T2 (de)
DK (1) DK0495265T3 (de)
ES (1) ES2061166T3 (de)
FI (1) FI101678B (de)
HU (1) HUT60484A (de)
IE (1) IE65406B1 (de)
NO (1) NO180417C (de)
NZ (1) NZ241217A (de)
PT (1) PT99954B (de)
ZA (1) ZA9110203B (de)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5505931A (en) * 1993-03-04 1996-04-09 The Dow Chemical Company Acid cleavable compounds, their preparation and use as bifunctional acid-labile crosslinking agents
EP0638583A1 (de) * 1993-08-13 1995-02-15 Hoechst Aktiengesellschaft Aminozucker Wirkstoffe, ein Verfahren zu ihre Herstellung und ihrer Verwendung als Arzneimittel
DE4433890C2 (de) * 1994-09-22 1999-02-18 Deutsches Krebsforsch Konjugat aus einem Wirkstoff und einem nicht als körperfremd angesehenen, nativen Protein
ATE234635T1 (de) * 1995-12-22 2003-04-15 Bristol Myers Squibb Co Verzweigte hydrazongruppen enthaltende kuppler
DE19636889A1 (de) * 1996-09-11 1998-03-12 Felix Dr Kratz Antineoplastisch wirkende Transferrin- und Albuminkonjugate zytostatischer Verbindungen aus der Gruppe der Anthrazykline, Alkylantien, Antimetabolite und Cisplatin-Analoga und diese enthaltende Arzneimittel
US6030997A (en) * 1998-01-21 2000-02-29 Eilat; Eran Acid labile prodrugs
US6800616B2 (en) 1998-02-26 2004-10-05 Supergen, Inc. Treatment of HIV infections
CA2248592A1 (en) 1998-08-31 2000-02-29 Christopher D. Batich Microspheres for use in the treatment of cancer
US6140015A (en) * 1998-12-10 2000-10-31 International Business Machines Corporation Photoresist compositions with pendant polar-functionalized aromatic groups and acid-labile branching
TWI242000B (en) * 1998-12-10 2005-10-21 Univ Southern California Reversible aqueous pH sensitive lipidizing reagents, compositions and methods of use
ID29246A (id) * 1999-03-11 2001-08-16 Ardenia Investments Ltd Senyawa-senyawa baru untuk pengobatan kanker
US6706892B1 (en) 1999-09-07 2004-03-16 Conjuchem, Inc. Pulmonary delivery for bioconjugation
BRPI0003386B8 (pt) * 2000-08-08 2021-05-25 Cristalia Produtos Quim Farmaceuticos Ltda pró-droga homo ou heterodiméricas úteis no tratamento de doenças ou disfunções mediadas por fosfodiesterases; composições farmacêuticas contendo a pró-droga ou seus sais farmacêuticos aceitáveis; processo de obtenção destas pró-drogas
JP2004511510A (ja) * 2000-10-16 2004-04-15 ネオファーム、インコーポレイティッド ミトキサントロンのリポソーム製剤
EP2163256B1 (de) 2001-05-11 2015-09-02 Ludwig Institute for Cancer Research Ltd. Spezifische Bindeproteine und deren Verwendungen
US20100056762A1 (en) 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
GB0116143D0 (en) * 2001-07-02 2001-08-22 Amersham Pharm Biotech Uk Ltd Chemical capture reagent
KR100507968B1 (ko) * 2001-08-18 2005-08-17 한국과학기술연구원 자기집합체를 형성하는 항암제-키토산 복합체 및 그의제조방법
CA2822457C (en) 2001-12-14 2016-03-08 The University Of Wyoming Methods and compositions for controlled resease of drugs
US8361464B2 (en) 2002-03-01 2013-01-29 Immunomedics, Inc. Anthracycline-Antibody Conjugates for Cancer Therapy
CA2478522A1 (en) * 2002-03-08 2003-09-18 Emory University Novel curcuminoid-factor viia constructs as suppressors of tumor growth and angiogenesis
US20050069551A1 (en) * 2002-03-08 2005-03-31 Emory University Cytotoxic compound-protein conjugates as suppressors of tumor growth and angiogenesis
WO2003100081A2 (en) 2002-05-24 2003-12-04 Mirus Corporation Biologically active maleamic acid derivatives with labile amide bonds
CN1733314A (zh) * 2004-08-11 2006-02-15 张阳德 半乳糖化白蛋白磁性阿霉素纳米粒的制备方法
WO2006052900A2 (en) * 2004-11-09 2006-05-18 University Of Southern California Targeted innate immunity
CN101137673B (zh) 2005-01-05 2013-12-04 比奥根艾迪克Ma公司 Cripto结合分子
EP2083866A4 (de) 2006-10-27 2011-12-28 Wei-Chiang Shen Lipidiertes interferon und verwendung
CN101711284A (zh) * 2007-01-25 2010-05-19 达娜-法勃肿瘤研究所 抗egfr抗体在治疗egfr突变体介导的疾病中的用途
CN101688229B (zh) * 2007-03-15 2013-06-12 路德维格癌症研究所 包含egfr抗体和src抑制剂的组合物及其在制备用于治疗哺乳动物癌症的药物中的用途
CN108424454B (zh) 2007-08-14 2022-05-31 路德维格癌症研究所有限公司 靶向egf受体的单克隆抗体175及其衍生物和用途
US8618096B2 (en) * 2008-07-21 2013-12-31 The Regents Of The University Of California Prodrug compositions and methods for using the same in treating cancer and malaria
JP5472288B2 (ja) * 2009-03-17 2014-04-16 国立大学法人 東京大学 タンパク質の電荷調節剤、及びタンパク質内包高分子ミセル複合体
WO2010111664A1 (en) * 2009-03-26 2010-09-30 Institute For Systems Biology Improved method to determine protein interaction sites
KR101962476B1 (ko) 2009-07-03 2019-03-26 아비펩 피티와이 리미티트 면역성 접합체 및 그 제조방법
US20110076232A1 (en) * 2009-09-29 2011-03-31 Ludwig Institute For Cancer Research Specific binding proteins and uses thereof
KR101961495B1 (ko) 2009-12-23 2019-03-22 아비펩 피티와이 리미티트 면역-컨쥬게이트 및 그 제조방법 ２
MX2013000250A (es) 2010-07-02 2013-10-28 Angiochem Inc Polipeptidos cortos y que contienen d-aminoacido para conjugados terapeuticos y usos de los mismos.
WO2013012733A1 (en) 2011-07-15 2013-01-24 Biogen Idec Ma Inc. Heterodimeric fc regions, binding molecules comprising same, and methods relating thereto
DK2744931T3 (en) 2011-08-18 2018-08-06 Affinity Biosciences Pty Ltd SOLUBLE POLYPEPTIDES
CA2860579A1 (en) 2012-01-10 2013-07-18 Biogen Idec Ma Inc. Enhancement of transport of therapeutic molecules across the blood brain barrier
GB201202268D0 (en) 2012-02-09 2012-03-28 Medical Res Council Intracellular immunity
WO2014057436A2 (en) 2012-10-10 2014-04-17 Adamed Sp. Z O.O. Anticancer conjugate
CN105209068A (zh) 2013-02-07 2015-12-30 免疫医疗公司 用于靶向癌症治疗的缀合至抗体的高效2-吡咯啉多柔比星的前药形式(p2pdox)
WO2014141094A1 (en) 2013-03-14 2014-09-18 Adamed Sp. Z O.O. Anticancer conjugate
EP3104857A4 (de) 2014-02-14 2017-10-11 The Regents of The University of California Cyclische peroxyde als prodrugs zur selektiven abgabe von wirkstoffen
EP3200765A4 (de) 2014-10-03 2018-05-30 EnGeneIC Molecular Delivery Pty Ltd Verbessertes laden von intakten, bakteriell abgeleiteten vesikeln mit kleinen molekülverbindungen
SI3331902T1 (sl) 2015-08-07 2021-09-30 ALX Oncology Inc. Konstrukti z domeno SIRP-alfa ali njegove različice
EA034582B1 (ru) 2015-08-07 2020-02-21 АЭлЭкс ОНКОЛОДЖИ ИНК. Конструкции варианта sirp-альфа и их применение
CA3006313C (en) 2015-11-24 2020-02-11 Transfert Plus, S.E.C. Peptide compounds and peptide conjugates for the treatment of cancer through receptor-mediated chemotherapy
US10800817B2 (en) 2016-12-19 2020-10-13 Morehouse School Of Medicine Compositions and methods for treating diseases by inhibiting exosome release
US10040831B2 (en) 2016-12-19 2018-08-07 Morehouse School Of Medicine Compositions and methods for treating diseases by inhibiting exosome release
BR112021024003A2 (pt) 2019-05-31 2022-04-19 Alx Oncology Inc Métodos de tratamento de câncer com fusão sirp alfa-fc em combinação com um inibidor de checkpoint imunológico
US11180534B1 (en) 2021-06-04 2021-11-23 Morehouse School Of Medicine Compositions and methods for treating SARS-CoV-2 infections
AU2023208050A1 (en) * 2022-01-14 2024-07-04 Regeneron Pharmaceuticals, Inc. Verrucarin a derivatives and antibody drug conjugates thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4631190A (en) * 1981-06-26 1986-12-23 Shen Wei C Acidity-sensitive spacer molecule to control the release of pharmaceuticals from molecular carriers
US4542225A (en) * 1984-08-29 1985-09-17 Dana-Farber Cancer Institute, Inc. Acid-cleavable compound
US4744981A (en) * 1985-10-17 1988-05-17 Neorx Corporation Trichothecene antibody conjugates
US4997913A (en) * 1986-06-30 1991-03-05 Oncogen pH-sensitive immunoconjugates and methods for their use in tumor therapy
US5140013A (en) * 1989-11-28 1992-08-18 Universite Laval Maleic anhydride derivatives used as conjugation agents of anti-tumor agents on desired carriers

Also Published As

Publication number Publication date
NO180417C (no) 1997-04-16
NO920040L (no) 1992-07-01
NO920040D0 (no) 1992-01-02
FI916131A (fi) 1992-07-01
AU646121B2 (en) 1994-02-10
ZA9110203B (en) 1993-01-27
HUT60484A (en) 1992-09-28
IE914567A1 (en) 1992-07-01
EP0495265B1 (de) 1994-08-03
NO180417B (no) 1997-01-06
HU914133D0 (en) 1992-03-30
PT99954B (pt) 1999-06-30
IE65406B1 (en) 1995-10-18
CA2058595A1 (en) 1992-07-01
JPH04334377A (ja) 1992-11-20
DE69103255T2 (de) 1994-12-08
DE69103255D1 (de) 1994-09-08
PT99954A (pt) 1993-06-30
FI101678B1 (fi) 1998-08-14
KR920012063A (ko) 1992-07-25
ATE109476T1 (de) 1994-08-15
US5306809A (en) 1994-04-26
FI101678B (fi) 1998-08-14
ES2061166T3 (es) 1994-12-01
AU9009891A (en) 1993-01-28
NZ241217A (en) 1993-12-23
EP0495265A1 (de) 1992-07-22
FI916131A0 (fi) 1991-12-27

Similar Documents

Publication Publication Date Title
DK0495265T3 (da) Syrelabile koblingsmolekyler
US4880935A (en) Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates
YU91503A (sh) Citotoksični imunokonjugati sa antitelima specifičnim za cd44
ATE294592T1 (de) Thioether enthaltende konjugate
FI912285A (fi) Nya bifunktionella kopplingsfoereningar, konjugat och foerfaranden foer framstaellning av dessa.
US4263279A (en) Pharmaceutically active compositions containing adriamycin and daunomycin
IL64722A (en) Immunoglobulin conjugates,their preparation and pharmaceutical compositions containing them
DK0384769T3 (da) Mærkning af proteiner
FI915780A0 (fi) Maerktae, modifierade oligonukleotider.
FI102077B1 (fi) Magneettisia proteiinikonjugaatteja, menetelmä niiden valmistamiseksi ja niiden käyttö
WO2004041307A3 (en) Compositions and methods for treating cancer using cytotoxic cd44 antibody immunoconjugates and radiotherapy
WO1996040664A3 (en) Preparation of immunogens and other conjugates of drugs
HUT70481A (en) Hepatotropic conjugates of antiviral drugs, carriers thereof and pharmaceutical compositions containing them